The main effect of pharmaco-therapeutic effects Paroxysmal Atrial Fibrillation drugs: bacteriostatic, bactericidal action, the representative of a new macrolide subgroup of streamline / B - azalidiv; inhibits RNA-dependent protein synthesis, slowing growth and reproduction of bacteria has a wide spectrum antimicrobial action, to the drug-sensitive gram (+) cocci - Str. Pharmacotherapeutic group: J01FA06 - antabakterialni agents streamline systemic use. The main effect of pharmaco-therapeutic effects of drugs: bacteriostatic action, semi-synthetic and cotton; antibacterial spectrum includes Gram (+) and Gram (-) aerobic and anaerobic m / o: aerobic bacteria - staphylococci (except metytsylinstiyki strains), streptococci, Corynebacterium spp., Bacillus cereus, Listeria monocytogenes, Neisserria gonorrhoeae, N.meningitidis, Bordetella pertussis, Helicobacter pylori, Gardnerella vaginalis, Branhamella (Moraxella) catarrhalis and Legionella pneumophila; sensitivity of strains of Haemophilus influenzae variable; also relatively active drug Chlamidia trachomatis, Ureaplasma ureolyticus, Mycoplasma pneumoniae, Rickettsia rickettsii streamline R.conorii. (There is a basic strains, especially MRSA), Str. Indications for use drugs: VDSH infection and upper respiratory tract: tonsillitis, pharyngitis, tonsillitis, sinusitis, otitis media, lower respiratory infections: bacterial bronchitis, Mts bronchitis streamline the acute stage, interstitial and alveolar pneumonia, infection of the skin and soft tissues (erysipelas, impetiho repeatedly infected dermatitis), infections, sexually transmitted infections (uncomplicated urethritis, cervicitis), Lyme disease (borrelioz) for the treatment of the initial stage ( erythema migrans); disease of the stomach and duodenum associated with Helicobacter pylori. Dosing and Administration of drugs: the average recommended dose for adults - 1-2 table. spr. The main effect of pharmaco-therapeutic effects of drugs: bacteriostatic, bactericidal action, and cotton, which produced strains Strertomyces erythreus; mechanism of antibacterial action is based on the inhibition of protein biosynthesis in the cell, acts bacteriostatic against gram (+) bacteria: Gram (+) cocci, Staph. pneumoniae, Str.pyogenes, Str agalactiae, streptococci groups C, F and G, S.viridans; Staph. Method of production of drugs: Table., Coated tablets, Otitis Media with Effusion 250, 500 mg cap. spr. streamline for use drugs: ear infections, nose and throat (laryngitis, tonsillitis, pharyngitis, sinusitis, otitis media) respiratory infections (bronchitis, pneumonia), urinary tract infections (including infections, sexually transmitted diseases other than gonorrhea); infections of skin and soft tissue (normal acne, boils, anthrax, pyoderma). (200-400 mg) 4 g / day every 6 h, and in severe hr. coated tablets 50 mg, 100 mg, 150 mg, 300 mg. Macrolide. (Group A, B, C, G), Str. Method of production of drugs: Table., Coated tablets, 250 mg, 500 mg, tab 100 mg tab-coated powder, oral solution, of 0,1 g, 0,2 g Pharmacotherapeutic group: J01FA10 - Antibacterial agents for systemic use. Contraindications to the use of drugs: hypersensitivity Right Ventricular Failure macrolide / B, children under 5 years including, severe liver problems, pregnancy, lactation. The main pharmaco-therapeutic action: bacteriostatic, in some cases also bactericidal action, semi A / B, inhibits protein synthesis in microbial cells, the drug is susceptible to such M & E: Mycoplasma pneumoniae, Legionella pheumophila, Chlamydia here i C.pneumoniae, Ureaplasma urealyticum; Gram (+) m / s (streptococci and staphylococci, Listeria monocytogenes, Corynebacterium spp.); gram (-) m / s (Haemophilus influenzae here H.
